Researchers have developed a new protocol for monitoring acute lymphoblastic leukemia (ALL), the most common cancer in children, to inform more effective treatment strategies and detect disease recurrence.
Chemotherapy drugs can induce mutations that lead to relapse in pediatric ALL patients
Chemotherapy has helped make acute lymphoblastic leukemia (ALL) one of the most survivable childhood cancers. Now, researchers working in the U.S., Germany and China have shown how chemotherapy drugs called thiopurines can lead to mutations that set patients up for relapse. The work appears today in the journal
Nature Cancer.
The research provides the first direct genomic and experimental evidence in pediatric cancer that drug-resistant mutations can be induced by chemotherapy and are not always present at diagnosis.
The findings offer a paradigm shift in understanding how drug resistance develops. The results also suggest possible treatment strategies for ALL patients who relapse, including screening to identify those who should avoid additional thiopurine treatment.
Share this article
Share this article
TORONTO, May 3, 2021 /PRNewswire/ -
Mountain Valley MD Holdings Inc. (the
Company or
MVMD ) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce that the Company has filed a novel cancer adjuvant patent and is proceeding with pre-clinical trials with third-party cancer Contract Research Organizations (CROs) in triple-negative breast cancer, metastatic melanoma, and lung carcinoma.
Summary
MVMD files cancer patent for direct intratumoral injection, intravenously, infusions or instillations as adjuvants for broad chemotherapeutic to immunotherapeutic cancer regimens.
The Company is proceeding with three separate pre-clinical trials with specialized third-party cancer CROs: (1) triple-negative breast cancer; (2) metastatic melanoma; and (3) Lewis Lung Carcinoma as a proxy for non-small cell lung carcinoma.